top of page

Non-CF Bronchiectasis

Young Parents


FDA-approved therapies for mucus symptoms in NCFBE


People living with NCFBE in the US


ARINA·1 may significantly improve the quality of life and long-term outcomes of people with NCFBE by thinning mucus and enabling its clearance out of the lungs, as well as acting as a potent anti-inflammatory agent within the airway. 

Non-cystic fibrosis bronchiectasis (NCFBE) is a disease characterized by dilated airways with mild to moderate airway obstruction and impaired mucociliary clearance that leads to a complex interplay of mucus accumulation and chronic neutrophil-predominant airway inflammation and damage. Typically, people with NCFBE suffer from chronic cough, sputum production, and frequent and recurring pulmonary infections, all of which lead to decreased quality of life, clinical decline, and premature death. To date, there are no FDA-approved therapies for mucus relief for people with NCFBE.

non-cf bronchiectasis-dot
Do you qualify?

Main Entry Criteria

  1. Diagnosis of NCFBE

  2. Predicted FEV1 greater than 40%

  3. Able to produce a sputum sample

  4. No new antibiotic, antiviral, or antifungal therapy within the last 28 days

  5. No cycled antibiotics (e.g., TOBI, Cayston) within the last 90 days

Current Status

Phase 2 Clinical Trial

Safety and efficacy of ARINA-1 in mild-to-moderate NCFBE

Primary Endpoint:



Secondary Endpoints:

Quality of life, impact of ARINA·1 on mucus rheology, airway and systemic inflammatory markers



28 days on therapy; 28 days off therapy.

Trial Number:


Patient Enrollment Status:

Enrollment Complete


Other Target Indications for ARINA·1

bottom of page